Management of blinding disease: Loss of immunity and superinfection

Eye

Volumn 19, Issue 10, 2005, Pages 1035-1036

  Evans, Barry G ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Binding disease; Global HIV impact; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BLINDNESS; CHILD NUTRITION; EDUCATION; EYE DISEASE; EYE INFECTION; FAMILY HEALTH; HEALTH CARE MANPOWER; HERPES ZOSTER OPHTHALMICUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INCOME; LYMPHOCYTE COUNT; MORTALITY; NONHUMAN; NUTRITIONAL STATUS; OPPORTUNISTIC INFECTION; PARENT; PREVENTIVE MEDICINE; RETINITIS; SUPERINFECTION; TREATMENT PLANNING; UNITED KINGDOM;

EID: 29244468262     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6701982     Document Type: Article

References (3)

1. The UK Collaborative Group for HIV and STI surveillance. Focus on Prevention. HIV and other Sexually Transmitted Infections in the United Kingdom in 2003. Health Protection Agency Centre for Infections: London, November 2004.
2. Montagnier L. Isolation of a T lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 200: 868-871.
3. Centers for Disease Control. Pneumocystis pneumonia - Los Angeles. Morbid Mortal Weekly Rep 1981; 30: 250-252.